RBC Capital Upgrades Medtronic(MDT.US) to Buy Rating, Raises Target Price to $105
Medtronic Is Maintained at Sector Perform by RBC Capital
Medtronic Analyst Ratings
RBC Capital Maintains Medtronic(MDT.US) With Hold Rating, Raises Target Price to $98
Bernstein Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $96
Bernstein Sticks to Its Buy Rating for Medtronic (MDT)
Goldman Sachs Adjusts Price Target on Medtronic to $84 From $82
Medtronic Is Maintained at Neutral by Citigroup
Medtronic Analyst Ratings
Evercore Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $104
Citi Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $92
TD Cowen Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $95
Medtronic's Buy Rating Justified by Growth in CST Sector and AiBLE's Market Integration
DBS Initiates Medtronic(MDT.US) With Hold Rating, Announces Target Price $90
Medtronic's Hold Rating: Financial Pressures and Market Shifts Impacting Profit Margins and Growth
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $100
Medtronic Buy Rating Affirmed: Sustained Growth and Strong Pipeline Drive Positive Outlook
Wells Fargo Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $106
Wells Fargo Remains a Buy on Medtronic (MDT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)